Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | HRH2 | P25021 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5290984 | 0.89 | MEN1 (0.44) | SIGMAR1POLBSMN1; SMN2CXCR4MEN1 | |
| SCHEMBL272713 | 0.88 | CXCR4 (0.46) | SIGMAR1POLBSMN1; SMN2CXCR4MEN1 | |
| SCHEMBL5544476 | 0.86 | CXCR4 (0.47) | SIGMAR1POLBSMN1; SMN2CXCR4MEN1 | |
| Hydrochloric Acid SCHEMBL27805378 | 0.85 | CXCR4 (0.46) | SIGMAR1POLBSMN1; SMN2CXCR4MEN1 | |
| SCHEMBL20407546 | 0.84 | — | — | |
| SCHEMBL27746939 | 0.80 | — | — | |
| SCHEMBL64778 | 0.80 | HRH3 (0.39) | POLBMEN1KMT2ALTA4HALDH1A1 | |
| SCHEMBL5236146 | 0.78 | SMN1; SMN2 (0.34) | SIGMAR1POLBSMN1; SMN2CXCR4MEN1 | |
| SCHEMBL271825 | 0.78 | HRH3 (0.42) | POLBSMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL28110383 | 0.78 | HRH3 (0.42) | POLBSMN1; SMN2MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113527270-B | Medical intermediate of PROTAC molecule targeting monoacylglycerol lipase, preparation method and application | 河南大学 | 2024-03-01 | — | — | CN | claimed |
| CN-113527270-A | Medicine intermediate of PROTAC molecule of targeted monoacylglycerol lipase, preparation method and application | 河南大学 | 2021-10-22 | — | — | CN | claimed |
| CN-109705033-A | N- heteroaryl sulfonamide analog derivative and preparation and application | 杭州壹瑞医药科技有限公司 | 2019-05-03 | — | — | CN | claimed |
| CN-109516969-A | One kind coumarin derivative containing carboxyl and its synthetic method and application | 山西大学 | 2019-03-26 | — | — | CN | claimed |
| EP-2758051-B1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-04-11 | — | — | EP | claimed |
| US-9328099-B2 | Cyanomethylpyrazole carboxamides as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-03 | — | — | US | claimed |
| CN-102656165-B | Glycoside derivatives and uses thereof | NOVARTIS AG | 2015-02-11 | — | — | CN | claimed |
| US-20140228348-A1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-14 | — | — | US | claimed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | claimed |
| CN-102656165-A | Glycoside derivatives and uses thereof | NOVARTIS AG | 2012-09-05 | — | — | CN | claimed |
| CN-101035525-A | Substituted urea derivatives for the treatment of cardiac diseases | CYTOKINETICS INC (US) | 2007-09-12 | — | — | CN | claimed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | claimed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | claimed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | claimed |
| US-20040147561-A1 | Pyrid-2-one derivatives and methods of use | SYNGENTA CROP PROTECTION AG (CH) | 2004-07-29 | — | — | US | claimed |
| EP-0171217-B1 | FUSED-RING HETEROCYCLIC COMPOUNDS A PROCESS FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE | SANKYO COMPANY LIMITED (JP) | 1989-05-03 | — | — | EP | claimed |
| US-4716162-A | BRAIN FUNCTION | SANKYO COMPANY, LIMITED (JP) | 1987-12-29 | — | — | US | claimed |
| EP-0171217-A2 | Fused-ring heterocyclic compounds a process for their production and their pharmaceutical use | SANKYO COMPANY LIMITED (JP) | 1986-02-12 | — | — | EP | claimed |
| CN-113527270-B | Medical intermediate of PROTAC molecule targeting monoacylglycerol lipase, preparation method and application | 河南大学 | 2024-03-01 | — | — | CN | disclosed |
| EP-0016746-A1 | New therapeutically active spirocycloalkylamines and pharmaceutical preparations comprising such compounds | Astra Läkemedel Aktiebolag (SE) | 1980-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | SIGMAR1 234/4885POLB 1637/4885SMN1; SMN2 3985/4885 |
| US-20140228348-A1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | JAK1, JAK2, JAK3 | SIGMAR1 1953/4885POLB 2976/4885SMN1; SMN2 4782/4885 |
| US-20040147561-A1 | Pyrid-2-one derivatives and methods of use | PLPBP, PNPO, PDXK | SIGMAR1 4091/4885POLB 912/4885SMN1; SMN2 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.